Liu Yi

[Expert Profile] Liu Yi, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in rheumatology and immunology in China, working in the Department of Rheumatology, West China Hospital, Sichuan University. He has long been dedicated to the clinical diagnosis, treatment, and scientific research of scleroderma, dermatomyositis, and various connective tissue diseases, and is a leading figure in rheumatology in western China.

[Education & Career] Professor Liu Yi graduated from West China University of Medical Sciences, completed systematic clinical training at West China Hospital, and further studied at famous international rheumatology centers, systematically mastering cutting-edge international rheumatic disease diagnosis and treatment techniques. He has long served as Director of the Rheumatology Department at West China Hospital, holding academic positions including standing committee member of the Rheumatology Branch of the Chinese Medical Association and Chair of the Rheumatology Branch of the Sichuan Medical Association. He has presided over grants from the National Natural Science Foundation of China and major provincial and ministerial projects, and is a discipline leader in rheumatology in western China.

[Areas of Expertise] Professor Liu specializes in the diagnosis and treatment of systemic sclerosis (scleroderma), dermatomyositis, polymyositis, Sjogren's syndrome, and various connective tissue diseases. He has extensive experience in comprehensive management of complex situations such as connective tissue diseases complicated with interstitial lung disease, pulmonary hypertension, and renal involvement. He is proficient in individualized application of immunosuppressive therapy and biologics, and excels at managing difficult and severe rheumatic disease patients, providing high-level diagnosis and treatment services for numerous rheumatic disease patients in western China.

[Academic Achievements & Industry Contributions] Professor Liu has led multiple clinical studies on connective tissue diseases, systematically evaluating the clinical features and treatment strategies of conditions such as scleroderma and dermatomyositis in Chinese patients, with findings published in authoritative domestic and international journals. He has actively participated in the development of Chinese rheumatology diagnosis and treatment guidelines and expert consensus statements, promoted the popularization of standardized rheumatic disease diagnosis and treatment in western China, and led the construction of regional rheumatology specialist alliances and teleconsultation platforms, significantly improving the overall diagnosis and treatment level of rheumatic diseases in western China, and making important contributions to narrowing the medical gap between eastern and western regions.

[Clinical Practice & Outstanding Contributions] For decades on the clinical front lines, Professor Liu has treated tens of thousands of patients with various rheumatic diseases, with patient coverage extending across the vast western region including Yunnan, Guizhou, Sichuan, and Chongqing. Leading his team, he has established a comprehensive multidisciplinary collaboration system for connective tissue diseases, providing clear diagnoses and disease control for countless scleroderma and dermatomyositis patients. He is enthusiastic about public welfare, having repeatedly organized grassroots rheumatology training and free clinics in western China. He is deeply trusted by patients and respected by peers alike, and is a pillar of rheumatology in western China.

[Honors & Reputation] Professor Liu Yi serves as Vice Chair of the Rheumatology Branch of the Chinese Medical Association and Chair of the Rheumatology Professional Committee of the Sichuan Medical Association, among other academic positions. He has presided over grants from the National Natural Science Foundation of China and major provincial and ministerial projects, and is a discipline leader in rheumatology in southwestern China. He has profound expertise in the diagnosis and treatment of scleroderma, dermatomyositis, and various connective tissue diseases. He has led the establishment of a rheumatology diagnosis and treatment collaboration network and patient cohort in southwestern China, promoted the implementation of early diagnosis and treat-to-target concepts, participated in the development of multiple rheumatology diagnosis and treatment guidelines, and has research findings published in authoritative domestic and international journals. For decades on the clinical front lines and grassroots support, he has trained a large number of rheumatology professionals, and is deeply trusted by patients and respected by peers alike.